RESUMO
Single image dehazing is a difficult problem because of its ill-posed nature. Increasing attention has been paid recently as its high potential applications in many visual tasks. Although single image dehazing has made remarkable progress in recent years, they are mainly designed for haze removal in daytime. In nighttime, dehazing is more challenging where most daytime dehazing methods become invalid due to multiple scattering phenomena, and non-uniformly distributed dim ambient illumination. While a few approaches have been proposed for nighttime image dehazing, low ambient light is actually ignored. In this paper, we propose a novel unified nighttime hazy image enhancement framework to address the problems of both haze removal and illumination enhancement simultaneously. Specifically, both halo artifacts caused by multiple scattering and non-uniformly distributed ambient illumination existing in low-light hazy conditions are considered for the first time in our approach. More importantly, most current daytime dehazing methods can be effectively incorporated into nighttime dehazing task based on our framework. Firstly, we decompose the observed hazy image into a halo layer and a scene layer to remove the influence of multiple scattering. After that, we estimate the spatially varying ambient illumination based on the Retinex theory. We then employ the classic daytime dehazing methods to recover the scene radiance. Finally, we generate the dehazing result by combining the adjusted ambient illumination and the scene radiance. Compared with various daytime dehazing methods and the state-of-the-art nighttime dehazing methods, both quantitative and qualitative experimental results on both real-world and synthetic hazy image datasets demonstrate the superiority of our framework in terms of halo mitigation, visibility improvement and color preservation.
RESUMO
BACKGROUND Regorafenib (RGF) is the drug of choice for treating hepatic carcinoma (HCC), but the drug has drawbacks due to resistance and associated adverse effects. Thus, it becomes crucial to understand the causal 'map' of the resistance conferred by RGF, so that its clinical potency can be amplified, resulting in enhanced efficacy with reduced adverse effects. Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells. Based on the literature, the present investigation was carried out to reveal the effect of RGF and MTF, with an expectation that MTF can synergize therapeutic potential as well reduce chances of resistance. MATERIAL AND METHODS Protein expression of hypoxia inducible factors (HIF)-2α, 30 kDa HIV Tat-interacting protein (TIP30), E-cadherin, N-cadherin, and pAMPK were assessed by Western blot analysis. RGF and MTF were exposed to MHCC97H cell and proliferation was quantified by assay of cell viability. Gene silencing and chromatin immunoprecipitation assay were done to reveal the relationship between TIP30 and HIF-2α. The impact of RGF and MTF together on postoperative recurrence and lung metastasis of hepatocellular carcinoma was investigated using tumor engrafted mice after administration of MTF and RGF once daily for 35 days. Immunohistochemistry was used to reveal CD31, Ki67, and TUNEL. RESULTS The results suggested MTF-RGF combination lowered expression of HIF-2α gene silencing and suggested increased TIP30 after reduction of HIF-2α. The chromatin immunoprecipitation study indicated that under hypoxia, HIF-2α could bind with TIP30 promoter. Cell number quantification (CCK8), viable cell count, and apoptosis data (using Annexin V-FITC) indicated co-administration of RGF and MTF reduced cell proliferation, encouraging cell apoptosis, and reduced epithelial-mesenchymal transition course. Thus, in orthotopic mice, the RGF-MTF combination exhibited substantial reduction of HCC in lung metastasis and postoperative relapse. CONCLUSIONS MTF can enhance the potential of RGF and inhibit the recurrence and metastasis of HCC after postoperative liver section by regulating the levels of TIP30 and HIF-2α.
Assuntos
Carcinoma Hepatocelular/tratamento farmacológico , Metformina/farmacologia , Compostos de Fenilureia/farmacologia , Piridinas/farmacologia , Acetiltransferases/efeitos dos fármacos , Acetiltransferases/metabolismo , Animais , Apoptose/efeitos dos fármacos , Fatores de Transcrição Hélice-Alça-Hélice Básicos/efeitos dos fármacos , Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo , Carcinoma Hepatocelular/genética , Hipóxia Celular , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Hepatectomia , Humanos , Hipóxia/metabolismo , Fígado/patologia , Fígado/cirurgia , Neoplasias Hepáticas/genética , Metformina/uso terapêutico , Camundongos , Camundongos Endogâmicos BALB C , Metástase Neoplásica/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/genética , Compostos de Fenilureia/uso terapêutico , Piridinas/uso terapêutico , Fatores de Transcrição/efeitos dos fármacos , Fatores de Transcrição/metabolismoRESUMO
Transition metal catalysts are particularly effective in improving the kinetics of the reversible hydrogen storage reaction for light metal hydrides. Herein, K2MoO4 microrods were prepared using a simple evaporative crystallization method, and it was confirmed that the kinetic properties of magnesium hydride could be adjusted by doping cubic K2MoO4 into MgH2. Its unique cubic structure forms new species in the process of hydrogen absorption and desorption, which shows excellent catalytic activity in the process of hydrogen storage in MgH2. The dissociation and adsorption time of hydrogen is related to the amount of K2MoO4. Generally speaking, the more K2MoO4, the faster the kinetic performance and the shorter the time used. According to the experimental results, the initial dehydrogenation temperature of MgH2 + 10 wt% K2MoO4 composite is 250 °C, which is about 110 °C lower than that of As-received MgH2. At 320 °C, almost all dehydrogenation was completed within 11 min. In the temperature rise hydrogen absorption test, the composite system can start to absorb hydrogen at about 70 °C. At 200 °C and 3 MPa hydrogen pressure, 5.5 wt% H2 can be absorbed within 20 min. In addition, the activation energy of hydrogen absorption and dehydrogenation of the composite system decreased by 14.8 kJ/mol and 26.54 kJ/mol, respectively, compared to pure MgH2. In the cycle-stability test of the composite system, the hydrogen storage capacity of MgH2 can still reach more than 92% after the end of the 10th cycle, and the hydrogen storage capacity only decreases by about 0.49 wt%. The synergistic effect among the new species MgO, MgMo2O7, and KH generated in situ during the reaction may help to enhance the absorption and dissociation of H2 on the Mg/MgH2 surface and improve the kinetics of MgH2 for absorption and dehydrogenation.